PMID- 29725474
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210305
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 15
IP  - 5
DP  - 2018 May
TI  - Telocinobufagin inhibits the epithelial-mesenchymal transition of breast cancer 
      cells through the phosphoinositide 3-kinase/protein kinase B/extracellular 
      signal-regulated kinase/Snail signaling pathway.
PG  - 7837-7845
LID - 10.3892/ol.2018.8349 [doi]
AB  - Telocinobufagin (TBG), an active ingredient of Venenumbufonis, exhibits an 
      immunomodulatory activity. However, its antimetastatic activity in breast cancer 
      remains unknown. The present study investigated whether TBG prevents breast 
      cancer metastasis and evaluated its regulatory mechanism. TBG inhibited the 
      migration and invasion of 4T1 breast cancer cells. Furthermore, TBG triggered the 
      collapse of F-actin filaments in breast cancer. The epithelial-mesenchymal 
      transition (EMT) markers, vimentin and fibronectin, were downregulated following 
      TBG treatment. However, E-cadherin was upregulated following TBG treatment. 
      Snail, a crucial transcriptional factor of EMT, was downregulated following TBG 
      treatment. Signaling pathway markers, including phosphorylated protein kinase B 
      (P-Akt), p-mechanistic target of rapamycin (mTOR) and p-extracellular 
      signal-regulated kinase (ERK), were decreased following TBG treatment. The same 
      results were obtained from in vivo experiments. In conclusion, in vitro and in 
      vivo experiments reveal that TBG inhibited migration, invasion and EMT via the 
      phosphoinositide 3-kinase (PI3K)/Akt/ERK/Snail signaling pathway in breast 
      cancer.
FAU - Gao, Yuxue
AU  - Gao Y
AD  - Department of Clinical Medicine, School of Clinical Medicine, Weifang, Shandong 
      261053, P.R. China.
FAU - Shi, Lihong
AU  - Shi L
AD  - Department of Pharmacology, Weifang Medical University, Weifang, Shandong 261053, 
      P.R. China.
FAU - Cao, Zhen
AU  - Cao Z
AD  - Department of Clinical Medicine, School of Clinical Medicine, Weifang, Shandong 
      261053, P.R. China.
FAU - Zhu, Xuetao
AU  - Zhu X
AD  - Department of Clinical Medicine, School of Clinical Medicine, Weifang, Shandong 
      261053, P.R. China.
FAU - Li, Feng
AU  - Li F
AD  - Department of Clinical Medicine, School of Clinical Medicine, Weifang, Shandong 
      261053, P.R. China.
FAU - Wang, Ruyan
AU  - Wang R
AD  - Department of Clinical Medicine, School of Clinical Medicine, Weifang, Shandong 
      261053, P.R. China.
FAU - Xu, Jinyuan
AU  - Xu J
AD  - Department of Clinical Medicine, School of Clinical Medicine, Weifang, Shandong 
      261053, P.R. China.
FAU - Zhong, Jinyi
AU  - Zhong J
AD  - Department of Clinical Medicine, School of Clinical Medicine, Weifang, Shandong 
      261053, P.R. China.
FAU - Zhang, Baogang
AU  - Zhang B
AD  - Department of Pathology, Key Clinical Specialty for Pathology of Shandong 
      Province, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 
      261053, P.R. China.
FAU - Lu, Shijun
AU  - Lu S
AD  - Department of Pathology, Key Clinical Specialty for Pathology of Shandong 
      Province, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 
      261053, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180326
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
EIN - Oncol Lett. 2021 Apr;21(4):242. PMID: 33664806
PMC - PMC5920466
OTO - NOTNLM
OT  - epithelial-mesenchymal transition
OT  - invasion
OT  - migration
OT  - snail
OT  - telocinobufagin
EDAT- 2018/05/05 06:00
MHDA- 2018/05/05 06:01
PMCR- 2018/03/26
CRDT- 2018/05/05 06:00
PHST- 2017/05/30 00:00 [received]
PHST- 2018/02/13 00:00 [accepted]
PHST- 2018/05/05 06:00 [entrez]
PHST- 2018/05/05 06:00 [pubmed]
PHST- 2018/05/05 06:01 [medline]
PHST- 2018/03/26 00:00 [pmc-release]
AID - OL-0-0-8349 [pii]
AID - 10.3892/ol.2018.8349 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 May;15(5):7837-7845. doi: 10.3892/ol.2018.8349. Epub 2018 Mar 
      26.